These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26803991)

  • 1. Hallmarks of hyperthermia in driving the future of clinical hyperthermia as targeted therapy: translation into clinical application.
    Issels R; Kampmann E; Kanaar R; Lindner LH
    Int J Hyperthermia; 2016; 32(1):89-95. PubMed ID: 26803991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and potential role of thermoradiotherapy for solid tumours.
    Hehr T; Wust P; Bamberg M; Budach W
    Onkologie; 2003 Jun; 26(3):295-302. PubMed ID: 12845217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current status of hyperthermia for deep-seated tumors].
    Hiraoka M; Abe M
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):289-96. PubMed ID: 2649000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperthermia adds to chemotherapy.
    Issels RD
    Eur J Cancer; 2008 Nov; 44(17):2546-54. PubMed ID: 18789678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
    Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
    Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin for the management of soft-tissue sarcoma.
    Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
    Le Cesne A; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
    Gennigens C; Jerusalem G
    Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.
    Schöffski P; Taron M; Jimeno J; Grosso F; Sanfilipio R; Casali PG; Le Cesne A; Jones RL; Blay JY; Poveda A; Maki RG; Nieto A; Tercero JC; Rosell R
    Eur J Cancer; 2011 May; 47(7):1006-12. PubMed ID: 21376569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule drugs - optimizing DNA damaging agent-based therapeutics.
    Hartley JA; Hochhauser D
    Curr Opin Pharmacol; 2012 Aug; 12(4):398-402. PubMed ID: 22503290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trabectedin for the treatment of relapsed ovarian cancer.
    Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P
    Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of hyperthermia in optimizing tumor response to regional therapy.
    Moyer HR; Delman KA
    Int J Hyperthermia; 2008 May; 24(3):251-61. PubMed ID: 18393003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperthermia in oncology.
    Falk MH; Issels RD
    Int J Hyperthermia; 2001; 17(1):1-18. PubMed ID: 11212876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and clinical results with the natural marine product ET-743.
    D'Incalci M; Jimeno J
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
    Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
    Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trabectedin--a targeted chemotherapy?
    von Mehren M
    Lancet Oncol; 2007 Jul; 8(7):565-7. PubMed ID: 17613417
    [No Abstract]   [Full Text] [Related]  

  • 17. Trabectedin for the treatment of breast cancer.
    D'Incalci M; Zambelli A
    Expert Opin Investig Drugs; 2016; 25(1):105-15. PubMed ID: 26592307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Going further in the knowledge of Yondelis®; what's new in clinical trials?
    Blay JY
    Future Oncol; 2014 Jun; 10(8 Suppl):s7-s12. PubMed ID: 25048046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
    Le Cesne A; Cresta S; Maki RG; Blay JY; Verweij J; Poveda A; Casali PG; Balaña C; Schöffski P; Grosso F; Lardelli P; Nieto A; Alfaro V; Demetri GD
    Eur J Cancer; 2012 Nov; 48(16):3036-44. PubMed ID: 22749255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
    Vincenzi B; Napolitano A; Frezza AM; Schiavon G; Santini D; Tonini G
    Pharmacogenomics; 2010 Jun; 11(6):865-78. PubMed ID: 20504257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.